Search This Blog

Wednesday, January 15, 2025

Amneal eyes meeting or beating views

 Amneal Pharmaceuticals updated its FY 2024 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 0.570-0.630 for the period, compared to the consensus estimate of 0.610. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.8 billion.

https://www.marketbeat.com/instant-alerts/amneal-pharmaceuticals-nasdaqamrx-releases-fy-2024-earnings-guidance-2025-01-15/

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.